Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA
1 other identifier
observational
100
1 country
1
Brief Summary
The present study aims to collect data regarding the history of the disease, previous and current treatments, and the clinical status of Dravet patients during the 3 months prior to stiripentol initiation, the first 3 months on stiripentol and the last 3 months on stiripentol (irrespective of stiripentol discontinuation).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 27, 2022
CompletedFirst Submitted
Initial submission to the registry
August 24, 2022
CompletedFirst Posted
Study publicly available on registry
September 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 28, 2024
CompletedAugust 2, 2024
August 1, 2024
2.2 years
August 24, 2022
August 1, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
management of the Dravet syndrome
Patient Information History of the Disease Clinical status of the patient during the 3 months preceding stiripentol treatment initiation Clinical status of the patient at stiripentol initiation Clinical status of the patient during the first 3 months of stiripentol treatment Clinical status of the patient during the last 3 months of stiripentol treatment Evolution on stiripentol
through study completion, an average of 1 year
Secondary Outcomes (1)
Better detection of the Dravet syndrome
through study completion, an average of 1 year
Interventions
Retrospective study
Eligibility Criteria
Patient with dravet syndrome and reated with stiripentol for a minimum of 3 months in routine practice
You may qualify if:
- Patients diagnosed with Dravet syndrome
- Treated with stiripentol for a minimum of 3 months in routine practice
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Biocodexlead
Study Sites (1)
Mayo clinic
Rochester, Minnesota, 55905, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 24, 2022
First Posted
September 16, 2022
Study Start
April 27, 2022
Primary Completion
June 28, 2024
Study Completion
June 28, 2024
Last Updated
August 2, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share